Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell

Maxime Niesen, MD^{1,2} ; Nicola Trotta, PhD^{2,3} ; Antoine Noel, MD¹ ; Tim Coolen, MD^{2,4} ; Georges Fayad, MD¹ ; Gil Leurkin-Sterk, MD, PhD^{2,3} ; Isabelle Delpierre, MD⁴ ; Sophie Henrard, MD^{2,5} ; Niloufar Sadeghi, MD, PhD⁴ ; Jean-Christophe Goffard, MD, PhD⁵ ; Serge Goldman, MD, PhD^{2,3} ; Xavier De Tiège, MD, PhD^{2,3}

¹Department of Otorhinolaryngology, CUB Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium.

²Laboratoire de Cartographie fonctionnelle du Cerveau, UNI — ULB Neuroscience Institute, Université libre de Bruxelles (ULB), Brussels, Belgium.

³Department of Nuclear Medicine, CUB Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium.

⁴Department of Radiology, CUB Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium

⁵Department of Internal Medicine, CUB Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium.

Corresponding Author:

Maxime Niesen, Laboratoire de Cartographie fonctionnelle du Cerveau, UNI - ULB Neurosciences Institute, Université libre de Bruxelles (ULB), 1070 Brussels, Belgium. Email: maxime.niesen@ulb.ac.be

Keywords: FDG-PET ; MRI ; COVID-19 ; Smell loss ;

Words count: 3975 words, **Abstract:** 230 words, **Character count of the title:** 91, **References:** 48

Declarations

Conflict of interest disclosure: None reported

Funding/Support: This work was supported by a special call “COVID-19” funded by the Université libre de Bruxelles, the Fonds Erasme (Brussels, Belgium) and the Fondation ULB (Brussels, Belgium). The PET-MR project at the CUB Hôpital Erasme and Université libre de Bruxelles is financially supported by the Association Vinçotte Nuclear (AVN, Brussels, Belgium). Tim Coolen is Clinical Master Specialist applicant to a PhD at the Fonds de la Recherche Scientifique (FRS-FNRS, Brussels, Belgium). Xavier De Tiège is Postdoctorate Clinical Master Specialist at the FRS-FNRS (Brussels, Belgium).

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study (collection, management, analysis, and interpretation of data); in the preparation, review and approval of the manuscript; and decision to submit the manuscript for publication.

Data availability: De-identified brain MRI and FDG-PET data can be shared upon reasonable request for scientific purpose and after approval of the CUB Hôpital Erasme Ethics Committee and authorities.

Standard protocol approvals, registrations, and patient consents: Studies were carried out at the CUB Hôpital Erasme (Brussels, Belgium). Participants contributed to the corresponding studies approved by the institutional Ethics Committee after written informed consent (References: P2020/204, CCB: B4062020000031; P2017/541, CCB: B406201734197).

Abstract

Objectives: Sudden loss of smell is a very common symptom of coronavirus disease 19 (COVID-19). This study characterizes the structural and metabolic cerebral correlates of dysosmia in patients with COVID-19.

Methods: Structural brain magnetic resonance imaging (MRI) and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) were prospectively acquired simultaneously on a hybrid PET-MR in twelve patients (2 males, 10 females, mean age: 42.6 years, age range: 23-60 years) with sudden dysosmia and positive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on nasopharyngeal swab specimens. FDG-PET data were analysed using a voxel-based approach and compared with that of a group of healthy subjects.

Results: Bilateral blocking of the olfactory cleft was observed in six patients, while subtle olfactory bulb asymmetry was found in three patients. No MRI signal abnormality downstream of the olfactory tract was observed. Heterogeneous (decrease or increase) glucose metabolism abnormalities were observed in core olfactory and high-order neocortical areas. A modulation of regional cerebral glucose metabolism by the severity and the duration of COVID-19-related dysosmia was disclosed using correlation analyses.

Conclusions: This PET-MR study shows that sudden loss of smell in COVID-19 is not related to central involvement due to SARS-CoV-2 neuroinvasiveness. Loss of smell is associated with heterogeneous cerebral metabolic changes in core olfactory and high-order cortical areas likely related to combined processes of deafferentation and active functional reorganisation secondary to the lack of olfactory stimulation.

Introduction

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible, since December 2019, of an ongoing worldwide outbreak of atypical and severe pneumonia, called coronavirus disease 2019 (COVID-19). Sudden loss of smell (i.e., anosmia) and taste (i.e., ageusia) are very common symptoms in SARS-CoV-2 infection, being reported in up to 80% of cases (for a review, see [1]).

SARS-CoV-2 infects human cells by binding to the angiotensin-converting enzyme 2 (ACE2) with contribution of the transmembrane protease serine 2 (TMPRSS2).[2] ACE2 and TMPRSS2 appear to be widely expressed by key support (sustentacular cells, Bowman's gland, microvillar cells) and stem cells of the olfactory epithelium (OE), but not by olfactory sensory neurons (OSNs).[1] How SARS-CoV-2 infection of OE cells leads to sudden smell loss remains hypothetical. The causal link might involve (i) blockage of the olfactory cleft due to focal OE inflammation, (ii) alteration of OSNs function, or (iii) widespread damage to OE and subsequently OSNs with variable time to recovery depending on the extent of stem cells damage.[1] Changes in olfactory bulbs (OB) and variable cortical (e.g., orbitofrontal cortex) or subcortical (e.g., thalamus, hypothalamus, brainstem) areas have also been disclosed by magnetic resonance imaging (MRI)[3–7] or positron emission tomography (PET)[8,9] in some COVID-19 patients with or without anosmia. Whether these central nervous system (CNS) abnormalities are indicative of potential SARS-CoV-2 neuroinvasion triggering anosmia is still a matter of debate.[1]

To get novel insights into the possible CNS involvement in COVID-19 patients with sudden anosmia, we used a hybrid PET and MRI system (PET-MR) to investigate the brain structure and regional glucose metabolism of SARS-CoV-2-infected patients with sudden loss of smell. We specifically searched for MRI signal and metabolic abnormalities along the olfactory

system and brain areas previously shown to be involved in the pathophysiology of non-COVID-19-related anosmia. We also searched for any sign of acute brain abnormalities.

Methods

Study design and participants

From April 2020 to the end of May 2020, dysosmic patients in the context of a SARS-CoV-2 infection were prospectively recruited at the CUB Hôpital Erasme based on the following criteria: (i) sudden loss of smell; (ii) positive SARS-CoV-2 detection (direct antigen detection or reverse transcriptase polymerase chain reaction) on nasopharyngeal swab specimen; (iii) no prior history of neurological, psychiatric, nasal, sinus or olfactory disorders; (iv) MRI compatibility; (v) formal acceptance to participate to the study.

Objective evaluation of olfactory dysfunction was performed using the “*identification test*” included in the Sniffin Sticks Battery (Burghart Messtechnik, Wedel, Germany) at the time of PET-MR data acquisition. The evolution of dysosmia was assessed at the time of manuscript submission using qualitative anamnesis and visual analog scale (0, no smell at all; 10, normal olfactory function). Clinical data were retrieved from patients’ anamnesis and medical records.

For PET data analyses, a PET-MR data set acquired in the context of other neuroimaging studies and composed of twenty-six healthy subjects (5 females, 21 males, mean age: 35 years, age range: 22-52 years) without any history of COVID-19, smell or taste disorders was used as control group.

Standard protocol approvals, registrations, and patient consents

Studies were carried out at the CUB Hôpital Erasme (Brussels, Belgium). Participants contributed to the corresponding studies approved by the institutional Ethics Committee after written informed consent (References: P2020/204, CCB: B4062020000031; P2017/541, CCB: B406201734197).

PET-MR data acquisition

Cerebral PET and MRI data were obtained using a 3T hybrid PET-MR scanner (SIGNA™, GE Healthcare, Chicago, IL) in accordance with COVID-19 institutional hygienic and safety rules.

MRI sequences have been described in details elsewhere.[5] They consisted in whole-brain axial 3D T1-weighted imaging (WI), axial T2WI, sagittal 3D T2WI fluid-attenuated inversion recovery (FLAIR), axial 3D susceptibility-WI (SWI), axial diffusion-WI (DWI), and a coronal T2WI centered on olfactory bulbs.

For PET data acquisitions, participants fasted for at least 4 hours, were awake in an eye-closed rest and received an intravenous bolus injection of 3-5 mCi (111-185 MBq) of [18F]-fluorodeoxyglucose (FDG) before PET-MR data acquisition. Forty minutes post-injection, a 20-min data acquisition was performed. PET data were reconstructed using the fully 3D iterative reconstruction algorithm VUE Point FX-S, which takes into account the time-of-flight (TOF) information and the correction for the point spread function (PSF) of the system. The algorithm was configured with 10 iterations, 28 subsets and a standard Z-axis filter cut-off at 4 mm. The photons' attenuation was corrected with a MRI-based map (MRAC) acquired simultaneously. PET images were displayed in a 256 x 256 x 89 matrix format, with a slice thickness of 2.78 mm. The reconstructed files were downloaded in their original format (DICOM, ECAT, Interfile) for meta-information and converted in NIfTI format for subsequent analysis.

MRI data analysis

MRI data were reviewed by two experienced neuroradiologists (T.C. and I.D.) following a systematic and comprehensive visual assessment procedure previously described.[5] Brain MRI findings were divided into recent (i.e., potentially related to SARS-CoV-2) and long-standing (i.e., unlikely related to SARS-CoV-2) changes.[5] The Lund-Mackay score for chronic

rhinosinusitis[10] was used for the visual assessment of incidental paranasal sinus inflammation and adapted to evaluate olfactory cleft obliteration (0: normal; 1: partial obliteration; 2: total obliteration) at the level of the OB. Final reports were then discussed with neurologists (S.G., X.D.T.), neuroradiologist (N.S.), otorhinolaryngologists (M.N., A.N., G.F.), and internists (S.H., J-C.G.)

PET data analysis

FDG-PET data were analyzed using the voxel-based Statistical Parametric Mapping software (SPM8, [http://www. fil.ion.ucl.ac.uk/spm/](http://www.fil.ion.ucl.ac.uk/spm/), Wellcome Trust Centre for Neuroimaging, London, UK) based on conventional subtractive and correlation analyses previously used by our group and described in details elsewhere.[11–15]

Briefly, PET images were spatially normalized into the Montreal Neurologic Institute template (MNI, Montreal Neurologic Institute, Quebec, Canada) and then smoothed using a 12-mm full-width at half-maximum Gaussian isotropic kernel. Global activity normalization was performed by proportional scaling.

For individual- and group-level subtractive analyses, we constructed general linear models (GLMs) of the preprocessed FDG-PET data of dysosmic patients —taken individually or as a group— and healthy subjects taken as separate groups. Separate *t*-contrasts identified brain areas where glucose metabolism was significantly lower or higher in dysosmic patient(s) compared to healthy subjects.

For correlation analyses, we constructed GLMs of the preprocessed FDG-PET data of dysosmic patients taken as one group. Scores of the *identification test* (Sniffin Sticks Battery) and duration (days) of smell loss were introduced as covariates of interest centered around condition means in separate GLMs. Separate *t*-contrasts identified brain regions showing significant positive

or negative correlations between the covariates of interest and regional cerebral glucose metabolism. For significant voxels, regression plots and associated slope coefficients/p-values (Pearson's correlation) between glucose metabolism and covariates of interest were obtained in Matlab R2017a (MathWorks Inc.).

Participant's age were introduced as covariate of no-interest in all GLMs to avoid potential ageing confounds. Gender was not used as covariate of no-interest considering the unbalanced gender profile between dysosmic patients and healthy subjects.

Results were considered significant at $p < .05$ corrected for multiple comparisons (Family Wise Error, FWE). To minimize type II errors, results were also deemed significant at $p < .001$ uncorrected (cluster size $k \geq 50$ voxels) if voxels involved brain areas previously reported as (i) involved in the processing of odors in healthy subjects[16–19], or as (ii) metabolically abnormal in COVID-19-related or non-COVID-19-related anosmia.[8,9,20–22]

Results

Patients' clinical characteristics

Table 1 describes the patients' clinical characteristics.

Fourteen patients (11 females, 3 males, mean age: 43 years, age range: 23–60 years) fulfilled the inclusion criteria. Two patients were excluded from further analyses due to magnetic artifacts covering the nasal cavity and orbitofrontal cortex (1 patient), and to the presence of a large right sylvian arachnoid cyst that would interfere with the normalization procedure (1 patient). Therefore, the final sample considered for the study was composed of 12 patients.

In those patients, subjective loss of smell occurred on average 15 days (+/- 9 days) before PET-MR data acquisition. It was the predominant symptom related to SARS-CoV-2 infection in seven patients. Other symptoms were dyspnea (five patients), asthenia (five patients) and gastrointestinal symptoms (three patients). Six patients also presented with headaches. One patient was hospitalized for the management of COVID-19 respiratory symptoms, while the others were outpatients.

Olfactory disorder was confirmed in each of the twelve SARS-CoV-2-positive patients by objective olfactory testing. The mean *identification test* score was 8/16 (+/- 1.4), and documented hyposmia in 5 patients (scores between 9 and 11) and anosmia in 7 patients (scores $\leq$ 8).

Positive evolution of dysosmia was observed in all patients. Five patients fully or almost fully recovered (4 to 10 weeks after onset; visual analog scale: 9 or 10). Seven patients still complained of relative hyposmia (improvement observed from 1 to 16 weeks after onset; visual analog scale: 6 to 8)

—Place Table 1 about here—

Structural MRI abnormalities

Table 2 and Figure 1 describe the MRI findings observed in dysosmic patients.

Subtle OB asymmetry was found in three patients with no associated bulbar signal abnormality. Four patients had no olfactory cleft obliteration, two had partial obliteration of one olfactory cleft, and six patients had bilateral olfactory cleft obliteration (bilateral and complete in four). Discrete signs of sinus inflammation were found in six patients (Lund-Mackay score less than 6). No sign of recent brain abnormality was found in any of the patients. Non-systematic long-standing brain MRI findings (e.g., periventricular halo, small arterial aneurysm, developmental venous anomaly, focal microbleed) were found in all but one patient. Of note, we did not find any significant correlation between the *identification test* score and the Lund-Mackay score of the olfactory cleft (Pearson correlation, $r = -0.178$, $p = 0.58$) or with the Lund-Mackay score of the paranasal sinuses (Pearson correlation, $r = 0.276$, $p = 0.39$).

—Place Table 2 and Figure 1 about here—

Regional cerebral glucose abnormalities

Tables 3-4 and Figures 2-4 describe the regional cerebral glucose abnormalities observed at the individual (Figure 2) and group (Figure 3) levels in dysosmic patients, as well as the results of correlation analyses (Figure 4).

—Place Table 3 about here—

At the individual-level, all patients showed significant ($p < .001$ uncorrected) decrease (3 patients) or increase (1 patient) in regional cerebral glucose metabolism, or a combination of both

(8 patients). Hypometabolic areas involved nodes of the core olfactory network (4 patients), somatosensory (1 patient) or visual (1 patient) cortical areas, the cerebellum (2 patients), or higher-order neocortical areas (9 patients) mainly encompassing the attentional, emotional or default mode (DMN) networks. Hypermetabolic areas also involved nodes of the core olfactory network (6 patients), the cerebellum (1 patient), or high-order neocortical areas (5 patients) belonging to the attentional network or the DMN.

—Place Figure 2 about here—

At the group-level, compared with healthy controls, dysosmic patients presented significant ($p < .001$ uncorrected) decrease in regional glucose consumption in bilateral dorso-lateral prefrontal cortex (DLPFC), bilateral frontal eye fields (FEF), and in the left anterior cingulate cortex (ACC). Significant ($p < .001$ uncorrected) hypermetabolic areas were also found in the right medial prefrontal cortex (MPFC), the left posterior parietal cortex (PCC) and in the left thalamus.

—Place Figure 3 about here—

Significant ($p < .001$ uncorrected) negative correlation was found between the *Identification test* score and cerebral glucose metabolism in the left FEF, the right orbitofrontal cortex and in the right PCC, indicating that a more severe deficit was related to a higher glucose metabolism in these brain regions.

Significant ($p < .001$ uncorrected) positive correlation was found between the duration of dysosmia and brain metabolism in bilateral orbitofrontal cortex, and in the left DLPFC,

MPFC and PPC, indicating that a longer duration of loss of smell was related to a higher glucose metabolism in these brain regions.

Of note, no significant correlation was found between the *Identification test* score and the duration of dysosmia (Pearson correlation, $r = 0.07$, $p = 0.82$).

—Place Figure 4 and Table 3 about here—

Discussion

This PET-MR study performed in twelve patients with sudden loss of smell due to SARS-CoV-2 infection demonstrates (i) bilateral obliteration of the olfactory cleft in 50% of the patients, (ii) subtle OB asymmetry in 25% of the patients, (iii) the absence of MRI signal abnormality downstream of the olfactory tract in all patients, (iv) heterogeneous glucose metabolism abnormalities mainly in nodes of olfactory and high-order networks, and (v) modulation of regional cerebral glucose metabolism by the intensity and the duration of SARS-CoV-2-related loss of smell.

Included patients were mainly young adults (mean age: 42.6 years) with a very low frequency of comorbidities (e.g., hypertension, diabetes) usually associated with severe forms of COVID-19. Their main symptoms were altered sense of smell and taste; the latter being reported by all but one patient. Objective assessment of taste was not available. Considering the recognized ambiguity between taste and smell perception,[23,24] we preferred not relying on subjective assessment of taste and we concentrated the objective clinical assessment on the smell deficit. About 50-67% of the patients also had clinical signs of cold with cough, rhinorrhea or fever. Only one patient was hospitalized in a non-intensive COVID-19 ward for the management of his respiratory distress while all the other were outpatients. Overall, the clinical characteristics of our patients' population are in line with those of SARS-CoV-2-positive patients with loss of smell and taste as predominant symptoms.[25–28] They contrast (in terms of age, comorbidities, clinical presentation) with those of patients with severe forms of COVID-19 who died in the same institution (i.e., CUB Hôpital Erasme) during the same period.[5]

The evolution of dysosmia was favourable in all patients but 58% of them still complained of incomplete recovery more than 15 weeks after the onset of symptoms. Long-lasting dysosmia

in these patients could be the secondary consequence of the death of OE support and stem cells; the latter playing a crucial role in regenerating OE.[1]

Structural MRI abnormalities

Bilateral (partial or complete) obliteration of the olfactory cleft was observed in about half of dysosmic patients. Other patients had either unilateral partial obliteration (three patients) or no MRI sign of olfactory cleft inflammation (four patients, one with signs of sinusitis). These findings are in line with imaging studies of the nasal cavity in COVID-19 patients with sudden loss of smell that either showed normal (see, e.g., [26,27,29]) or focal inflammation of the OE with obliteration of the olfactory cleft (see, e.g., [26,30]). This demonstrates that obliteration of the olfactory cleft due to focal OE inflammation is not the only possible pathophysiological mechanism underlying SARS-CoV-2-related dysosmia.[1]

Three dysosmic patients showed subtle OB asymmetry, with no OB MRI signal abnormality. One had complete and bilateral obliteration of the olfactory cleft, while the two others had either partial unilateral obliteration or no sign of OE inflammation at all. Previous MRI studies have demonstrated MRI changes in OB in patients with SARS-CoV-2-related anosmia[3,4,26] or in non-survivors of severe COVID-19,[5] suggesting some degree of central involvement at the origin of dysosmia in a subset of patients[1]. Results of the present study show that SARS-CoV-2-related OB involvement is not the main mechanism at the basis of acute loss of smell in COVID-19. Whether these OB abnormalities are associated with direct infection of OSNs or mitral cells remains doubtful considering the absence of ACE2 expression demonstrated in these cells.[1] Infection of vascular pericytes in the OB—in which there is evidence of ACE2 expression—might actually be responsible for OB MRI signal abnormalities found in some dysosmic patients.

This hypothesis would be consistent with clinical evidence showing that SARS-CoV-2 predominantly influences the brain indirectly through effects on brain vasculature.[1]

No acute MRI signal abnormality was found downstream of the olfactory tract (or the rest of the brain), which is in line with most previous MRI studies performed in anosmic or severe forms of COVID-19 (see, e.g.,[3,5]). Still, rare cases of possible SARS-CoV-2-related limbic encephalitis have been reported in the literature (see, e.g., [31–33]), suggesting that SARS-CoV-2 might potentially reach the brain via, e.g., the olfactory nerves, like other neurotropic viruses such as herpes simplex virus.[34,35] Still, the question remains open since limbic encephalitis might be para-infectious (i.e., without local viral involvement) and the neuroinvasive capacity of SARS-CoV-2 to directly infect neurons remains, to the best of our knowledge, yet unproven.[1] MRI data from the present study do not support the involvement of central olfactory pathways in SARS-CoV-2-related sudden loss of smell.

Of note, a COVID-19 patient has been reported with FLAIR hyperintensities bilaterally in the OB and in the right gyrus rectus/orbitofrontal cortex four days after the onset of SARS-CoV-2-related anosmia.[3] In that case, FLAIR abnormalities resolved 28 days later on a subsequent MRI.[3] Based on this single case report, it might be speculated that OB and brain MRI abnormalities are only present at the very early phase of sudden loss of smell.[3] In this study, all PET-MR investigations were performed during the patients' symptomatic phase, with 60% of them done >10 days after the onset of dysosmia. We cannot therefore exclude that some of our negative MRI findings are due to the rather late nasal and brain imaging. Further longitudinal studies are needed to better characterize the chronology of MRI abnormalities in this condition.

Regional brain glucose metabolism abnormalities

At the individual level, heterogeneous (either decrease or increase) regional cerebral glucose metabolism abnormalities were found, in the core olfactory network and in other brain areas belonging to other sensory or high-level cognitive networks, as well as within the cerebellum. This finding highlights the absence of a clear and reproducible brain metabolic pattern across patients with SARS-CoV-2-related sudden loss of smell. These heterogeneous findings translate at the group-level into rather subtle ($p < .001$ uncorrected) regional decreases and increases in glucose consumption that, unexpectedly, did not mainly involve nodes of the core olfactory network *per se* (apart from the thalamus), but rather high-order neocortical areas. Although surprising at first glance, these individual- and group-level results are in line with (i) results of fMRI studies performed in healthy subjects showing that odor processing not only recruits the core olfactory network but also other brain structures such as high-order neocortical areas (for reviews, see, e.g., [16,36]), (ii) results of structural MRI investigations showing that dysosmic patients from various causes present changes in grey matter volume in numerous high-order neocortical areas similar to those observed in our population (see [37] for a review), and (iii) results of functional neuroimaging investigations done in dysosmic patients during olfactory stimulation, showing significant changes in the activity of similar high-order neocortical areas compared with healthy subjects.[20,37–39] Functional neuroimaging studies performed in humans have demonstrated that, while smelling single odors activates the core olfactory network, higher-level olfactory tasks (i.e., discrimination of odor quality, odor recognition memory or odor familiarity judgement) recruit brain areas outside the core olfactory network, including the cerebellum, cortices involved in other sensory modalities such as somatosensory or visual functions, and brain areas involved in high-order functions (for reviews, see [16,36,40]). The more complex the olfactory task is, the more remote these high-order areas are in terms of connexion with the core olfactory network.[16] These long-range connections explain part of the olfactory experience, i.e., odors can immediately

elicit strong emotions, memories and mental images.[16] In light of this body of evidence, our results lead us to the hypothesis that SARS-CoV-2-related sudden loss of smell induces changes in glucose consumption in core olfactory and other brain areas due to alterations in both basic and higher olfactory functions.

Critically, correlations analyses between regional cerebral glucose metabolism and the severity/duration of SARS-CoV-2-related smell loss brought additional insights into the origin of the heterogeneity of the metabolic changes observed at the individual level. They indeed revealed a modulation of brain glucose consumption by the severity (negative correlation with the score on the “*identification test*”) and the duration (positive correlation) of dysosmia. Intriguingly, severe loss of smell (as documented by a low score on the “*identification test*”) was associated with a higher glucose metabolism in some olfactory core (e.g., orbitofrontal cortex) and high-order brain areas (FEF and PCC), while patients with more preserved olfactory function had lower glucose metabolism in these brain areas. Although these results appear rather counterintuitive, they are in line with those of a previous FDG-PET study, which also showed a negative correlation of regional glucose consumption with the level of loss of smell.[21] By contrast, longer duration of loss of smell was associated with a higher glucose metabolism in some core (e.g., orbitofrontal cortex) and high-order brain areas (DLPFC, MPFC, PCC). Importantly, no correlation was found between the intensity and the duration of smell loss. These correlation data shed light on the mixed, and somehow divergent, findings of individual- and group-level analyses on dysosmic patients. The regional decrease in metabolism, essentially observed in patients with moderate smell loss, is probably attributable to a deafferentation phenomenon as observed, e.g., in sudden visual loss due to non-infectious disorders.[41,42] By contrast, the increased or preserved metabolism, essentially associated with either severe or long-lasting loss of smell, could be related to functional reorganization/plasticity mechanisms. Such mechanisms involve, in particular, compensatory

processes, unmasking of already existing but inactive neural connections, or the avoidance of maladaptive neural processes.[43] The hyperactivity of some brain areas may also relate to some forms of olfactory mental imaging associated with spontaneous repetitive odor search,[44] or to emotional/behavioral consequences of severe or prolonged anosmia.[45]

Considering that metabolic abnormalities were not associated with any MRI signal abnormality, they probably do not represent neuroimaging evidence supporting the neuroinvasive potential of the SARS-CoV-2 but rather functional cerebral markers of the olfactory deficit.

Limitations of the study

PET-MR data were acquired in patients at different moments after the onset of dysosmia with no longitudinal neuroimaging follow-up. Although this approach proved its value in correlation analyses with regional cerebral metabolism, it did not allow proper characterization of the chronology of structural and metabolic abnormalities in COVID-19-related dysosmia.

This study did not include any objective evaluation of taste function as it was not available at our center at the start of the COVID-19 pandemic and was very difficult to obtain during this sanitary crisis. Considering that all but one patient complained about altered sense of taste, it would have been of great interest to investigate the brain metabolic changes specifically associated with dysgeusia. As discussed above, due to the recognized ambiguity between taste and smell perception,[23,24] we decided not to include any correlation analyses with the subjective evaluation of taste (i.e., visual analogue scale).

For voxel-based FDG-PET data analyses, we relied on a group of healthy subjects who had undergone PET-MR imaging in the context of an unrelated neuroimaging study. This was due to the difficulty to perform neuroimaging research investigations in healthy subjects in an academic hospital environment during the ongoing COVID-19 pandemics. For that reason, healthy subjects

did not undergo any objective or subjective evaluation of smell and taste at the time of the PET-MR data acquisition. Also, the group of healthy subjects was not properly matched for age and sex with the included COVID-19 patients. Therefore, age was introduced as a covariate of non-interest in voxel-based FDG-PET data analyses, which limits the potential confound associated with this variable in our results. A similar approach could not be applied to accommodate the gender unbalance between patients and control groups, but the findings do not match reported gender differences in cerebral glucose metabolism [46–48], while being in line with results of previous FDG-PET studies on dysosmia.[9,20,21]

Conclusions

This PET-MR study demonstrates that the main pathophysiological hypotheses (i.e., obliteration of the olfactory cleft, central involvement due to SARS-CoV-2 neuroinvasiveness) raised to explain sudden smell loss in COVID-19 do not explain dysosmia in all patients. It also shows that smell loss is associated with heterogeneous cerebral metabolic changes in core olfactory and other brain areas suggesting possible combined processes of deafferentation and active functional reorganization secondary to the lack of olfactory sensory stimulation. Based on those findings, SARS-CoV-2-infection limited to OE support and stem cells might be the predominant pathophysiological mechanisms involved in COVID-19 sudden loss of smell, with variable interindividual structural and functional consequences.

Acknowledgments

The authors would like to express their most sincere gratitude to the PET-MR technologists who made this work possible, i.e., Maria Coelho De Vasconcelos, Ana Peralta Pereira, and Joao Marinho Ribeiro.

Figure and Table

Table 1 : Clinical characteristics of the patients

Clinical characteristic	% of Patients ($n_{tot} = 12$)
Mean age (range), years	42.6 (23 – 60)
Mean Body Mass Index (range), kg/m²	24.8 (22 – 29.8)
Female gender	83.3 (10)
Active smoker	8.3 (1)
Hospitalisation	8.3 (1)
SARS-CoV-2 detection	
Direct antigen detection	25 (3)
Reverse transcriptase PCR	75 (9)
Comorbidities	
Respiratory allergy	50 (6)
Asthma	8.3 (1)
Hypertension	16.7 (2)
Hypothyroidism	8.3 (1)
Diabetes	0
Symptoms	
Dysosmia	100 (12)
Dysgueusia	91.7 (11)
Myalgia, Arthralgia	75 (10)
Cough	66.7 (8)
Rhinorrhea	66.7 (8)
Fever	50 (6)
Headache	50 (6)
Dyspnea	41.7 (5)
Asthenia	41.7 (5)
Diarrhea	25 (3)
Nausea, Vomiting	16.7 (2)
Rash	8.3 (1)
Throat pain	8.3 (1)
Objective olfactory assessment	
Anosmia	58.3 (7)
Hyposmia	41.7 (5)

Table 2 : Structural MRI Findings

Patient	IT Score	Asymmetry of Olfactory bulbs	Olfactory clefts		Paranasal sinuses							
			Right	Left	Right				Left			
					F	E	S	M	F	E	S	M
1	9	-	0	0	0	0	0	0	0	0	0	0
2	6	-	0	0	0	0	0	0	0	0	0	2
3	10	-	0	0	0	1	1	1	0	1	0	1
4	9	-	1	2	0	0	0	0	0	0	0	0
5	5	-	2	2	0	1	0	0	0	0	0	0
6	8	-	1	2	0	0	0	0	0	0	0	0
7	8	Left > Right	2	2	0	0	0	0	0	0	0	0
8	9	-	2	2	1	1	1	1	0	1	0	1
9	7	Left > Right	0	1	0	0	0	0	0	0	0	0
10	8	Left > Right	0	0	0	0	0	0	0	1	0	0
11	8	-	2	2	0	0	0	0	0	0	0	0
12	9	-	1	0	0	0	0	0	0	0	0	0

IT = identification test ; F = frontal ; E = Ethmoidal ; S = Sphenoid ; M = Maxillary ;

Lund-MacKay Score : 0 = no sign of inflammation (tolerance for small cysts or visible mucosal lining < 1 mm), 1 = signs of inflammation or partial obliteration, 2 = total obliteration

Figure 1 : Axial T2-weighted coronal images demonstrating bilateral and complete obliteration of the olfactory clefts (**a**) with no associated olfactory bulb asymmetry and (**b**) with asymmetry of the olfactory bulbs (left (L) bulb relatively enlarged) .

Table 3 : MNI coordinates, cluster size (k) and t-value (T) of cortical areas with significant hypo- and hypermetabolism (**a**) at the group-level, and (**b**) at the individual-level.

#	Region	MNI Coordinates			Cluster-size	T-score
		x	y	z		
Hypometabolism						
a. Group-level						
	FEF	32	-14	62	113	4.51
		-36	-8	56	77	4.13
	DLPFC	-48	4	30	209	4.37
		22	10	58	87	4.06
	Anterior cingular cortex	-6	22	24	142	3.78
b. Individual-level						
1	FEF	-44	48	12	1606	5.78
		26	56	12	340	5.66
		-26	22	58	80	4.63
		26	14	60	70	4.19
	Posterior parietal cortex	48	-66	30	140	4.89
		40	-66	50	153	4.81
		-36	-42	70	127	4.16
	Anterior cingular cortex	2	34	32	1305	5.04
	MPFC	4	26	58	143	4.81
	DLPFC	50	22	24	78	3.93
2	Posterior parietal cortex	-34	-48	68	60	3.91
		34	-42	64	50	3.84
3	Piriform cortex	-16	26	-30	207	5.96
	Hippocampus	24	-16	-20	90	4.08
4	SMC	10	4	72	68	5.35
	DLPFC	44	10	32	74	4.64
5	Post-central gyrus	22	-28	72	73	4.83
	Posterior parietal cortex	-20	-72	58	82	4.80
		44	-22	56	60	4.35
	Insula	46	12	-4	91	4.57
	VLPFC	-58	10	28	74	4.29
6	FEF	28	14	58	386	6.39
	VLPFC	-58	20	30	110	5.20
	Posterior parietal cortex	-36	-52	66	68	4.58
		46	-52	56	63	4.41
	Superior frontal gyrus	-10	12	66	177	4.13
	Inferior parietal lobule	60	-22	42	20	3.77
7	n.s.					
8	Middle temporal gyrus	60	-36	-2	84	4.92
	Orbitofrontal cortex	38	20	-12	420	4.53
	Piriform cortex	-30	24	-22	67	4.28
9	Insula	32	-16	12	311	5.61
	Cuneus	-14	-74	34	357	4.99
	Occipital cortex	34	-86	14	93	4.49
	Vermis	0	-48	-38	106	4.14
	Hippocampus	26	-18	-20	58	4.09
	Middle temporal gyrus	60	-4	-20	116	4.07
	Orbitofrontal cortex	2	16	-18	70	4.04
	Lingual gyrus	-8	-88	-6	220	3.93
		-10	-60	-2	73	3.39
10	Middle temporal gyrus	62	-4	-18	345	4.96
	Cerebellum	40	-44	38	103	4.44
	Posterior cingular cortex	6	-52	14	80	4.09
11	DLPFC	-44	6	28	58	4.80
12	Thalamus	-14	-22	14	263	5.03

#	Region	MNI Coordinates			Cluster-size	T-score
		x	y	z		
Hypermetabolism						
a. Group-level						
	MPFC	30	38	0	52	4.36
	Posterior parietal cortex	-24	-42	82	55	4.23
	Thalamus	-24	-18	8	89	4.05
b. Individual-level						
1	Cerebellum	-30	-42	-46	1811	6.13
		10	-44	-50	118	4.06
	Thalamus	-26	-26	6	398	4.56
2	n.s.					
3	n.s.					
4	Anterior temporal pole	-40	4	-38	97	3.83
5	Anterior temporal pole	-32	14	-36	119	4.67
6	Orbitofrontal cortex	38	28	-26	142	4.85
	Piriform cortex	-30	22	-30	89	4.44
	Anterior temporal pole	48	2	-16	52	4.16
	Hippocampus	-24	8	-16	61	4.07
7	DLPFC	38	48	30	56	4.75
8	n.s.					
9	Precuneus	-14	-58	42	152	5.21
	Precuneus	10	-60	42	135	4.79
	Posterior parietal cortex	50	-66	38	53	4.17
10	DLPFC	42	52	4	137	4.59
	Posterior parietal cortex	42	-68	32	112	4.52
11	FEF	32	10	44	152	5.35
		-34	16	36	117	4.60
	Posterior parietal cortex	-28	-44	52	156	4.46
12	Precuneus	-8	-58	48	435	6.06
	Orbitofrontal cortex	-26	44	-14	102	4.44
		32	40	-14	155	4.06
	SMC	-16	-26	56	99	4.28

DLPFC: dorso-lateral prefrontal cortex; VLPFC: ventro-lateral prefrontal cortex; FEF: frontal eye fields; SMC: supplementary motor cortex; MPFC: medial prefrontal cortex; n.s.: non-significant

Figure 2 : Regional hyper- and hypometabolism in two typical patients.

Legend: Images are thresholded at $p < .001$ uncorrected ($k \geq 50$ voxels).

Figure 3 : Regional cerebral glucose metabolic abnormalities observed at the group-level

Legend: Regional hypometabolism (Top) and hypermetabolism (Bottom) observed at the group level. Images are thresholded at $p < .001$ uncorrected ($k \geq 50$ voxels).

Table 4 : MNI coordinates, cluster size (k), Pearson's correlation coefficient (r) and T-score of cortical areas with significant correlation between the olfactory function (assessed by the *Identification test* score) and cerebral glucose metabolism; and between the duration of smell loss and brain metabolism.

Covariate of interest	Region	MNI Coordinates			Cluster-size	Pearson's r	T-score
		x	y	z			
Olfactory function	FEF	-30	6	48	87	-0.97	12.60
	Posterior parietal cortex	22	-54	46	60	-0.94	8.20
	Orbitofrontal cortex	12	68	0	88	-0.92	7.07
		38	54	-10	61	-0.92	6.68
Duration of anosmia	MPFC	0	48	46	113	0.96	10.25
		-6	32	62	68	0.93	8.08
	DLPFC	-38	32	34	143	0.94	8.73
		-48	24	18	87	0.90	6.32
	Orbitofrontal cortex	28	66	0	50	0.91	6.57
		-34	32	-10	66	0.90	6.44
		36	34	-14	198	0.89	5.97
	Posterior parietal cortex	-24	-66	54	73	0.90	6.25

DLPFC: dorso-lateral prefrontal cortex; FEF: frontal eye fields; MPFC: medial prefrontal cortex

Figure 4 : Results of the correlation analyses performed between the cerebral glucose metabolism and the severity of olfactory dysfunction, and between the cerebral glucose metabolism and the duration of anosmia. **(a)** Regression plots of the severity of olfactory dysfunction (assessed by *the identification test score*) and adjusted metabolic responses obtained by considering the peak voxel in the left FEF ($[-30\ 6\ 48]$, Pearson's correlation: $r = 0.97, p < .001$) and in the right orbitofrontal cortex ($[12\ 68\ 0]$, Pearson's correlation: $r = 0.94, p < .001$). **(b)** Regression plots of the duration of anosmia and adjusted metabolic responses obtained by considering the peak voxel in the left DLPFC ($[-38\ 32\ 34]$, Pearson's correlation: $r = 0.94, p < .001$) and in the left orbitofrontal cortex ($[-34\ 32\ -10]$, Pearson's correlation: $r = 0.9, p < .001$).

References

1. Cooper KW, Brann DH, Farruggia MC, Bhutani S, Pellegrino R, Tsukahara T, et al. COVID-19 and the Chemical Senses: Supporting Players Take Center Stage. *Neuron*. 2020;107:219–33.
2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell*. 2020;181:271–80.e8.
3. Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia [Internet]. *JAMA Neurology*. 2020. Available from: <http://dx.doi.org/10.1001/jamaneurol.2020.2125>
4. Laurendon T, Radulesco T, Mugnier J, Grault M, Chagnaud C, El Ahmadi A-A, et al. Bilateral transient olfactory bulbs edema during COVID-19-related anosmia. *Neurology* [Internet]. 2020; Available from: <http://dx.doi.org/10.1212/WNL.0000000000009850>
5. Coolen T, Lolli V, Sadeghi N, Rova A, Trotta N, Taccone FS, et al. Early postmortem brain MRI findings in COVID-19 non-survivors. *Neurology* [Internet]. 2020; Available from: <http://dx.doi.org/10.1212/WNL.0000000000010116>
6. Klironomos S, Tzortzakakis A, Kits A, hberg C, Kollia E, Ahromazdae A, et al. Nervous System Involvement in COVID-19: Results from a Retrospective Consecutive Neuroimaging Cohort. *Radiology*. 2020;202791.
7. Arago MFVV, Leal MC, Cartaxo Filho OQ, Fonseca TM, Valena MM. Anosmia in COVID-19 Associated with Injury to the Olfactory Bulbs Evident on MRI. *AJNR Am J Neuroradiol* [Internet]. 2020; Available from: <http://dx.doi.org/10.3174/ajnr.A6675>
8. Guedj E, Million M, Dudouet P, Tissot-Dupont H, Bregeon F, Cammilleri S, et al. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? [Internet]. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020. Available from: <http://dx.doi.org/10.1007/s00259-020-04973-x>
9. Karimi-Galougahi M, Yousefi-Koma A, Bakhshayeshkaram M, Raad N, Haseli S. FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19. *Acad Radiol*. 2020;27:1042–3.
10. Lund VJ, Mackay IS. Staging in rhinosinusitis. *Rhinology*. 1993;31:183–4.
11. Trotta N, Goldman S, Legros B, Ligot N, Guerry N, Baete K, et al. Metabolic evidence for episodic memory plasticity in the nonepileptic temporal lobe of patients with mesial temporal epilepsy. *Epilepsia*. 2011;52:2003–12.
12. De Tige X, Goldman S, Laureys S, Verheulpen D, Chiron C, Wetzburger C, et al. Regional cerebral glucose metabolism in epilepsies with continuous spikes and waves during sleep. *Neurology*. 2004;63:853–7.
13. De Tige X, Ligot N, Goldman S, Poznanski N, de Saint Martin A, Van Bogaert P. Metabolic evidence for remote inhibition in epilepsies with continuous spike-waves during sleep. *Neuroimage*. 2008;40:802–10.
14. Trotta N, Archambaud F, Goldman S, Baete K, Van Laere K, Wens V, et al. Functional integration changes in regional brain glucose metabolism from childhood to adulthood. *Hum Brain Mapp*.

2016;37:3017–30.

15. Trotta N, Goldman S, Legros B, Baete K, Van Laere K, Van Bogaert P, et al. Changes in functional integration with the non-epileptic temporal lobe of patients with unilateral mesiotemporal epilepsy. *PLoS One*. 2013;8:e67053.

16. Savic I. Brain imaging studies of the functional organization of human olfaction. *Neuroscientist*. 2002;8:204–11.

17. Levy LM, Henkin RI, Hutter A, Lin CS, Martins D, Schellinger D. Functional MRI of human olfaction. *J Comput Assist Tomogr*. 1997;21:849–56.

18. Zhou G, Lane G, Cooper SL, Kahnt T, Zelano C. Characterizing functional pathways of the human olfactory system. *Elife* [Internet]. 2019;8. Available from: <http://dx.doi.org/10.7554/eLife.47177>

19. Qureshy A, Kawashima R, Imran MB, Sugiura M, Goto R, Okada K, et al. Functional mapping of human brain in olfactory processing: a PET study. *J Neurophysiol*. 2000;84:1656–66.

20. Micarelli A, Chiaravalloti A, Danieli R, Schillaci O, Alessandrini M. Cerebral metabolic changes related to clinical parameters in idiopathic anosmic patients during olfactory stimulation: a pilot investigation. *Eur Arch Otorhinolaryngol*. 2017;274:2649–55.

21. Kim YK, Hong S-L, Yoon EJ, Kim SE, Kim J-W. Central presentation of postviral olfactory loss evaluated by positron emission tomography scan: a pilot study. *Am J Rhinol Allergy*. 2012;26:204–8.

22. Poellinger A, Thomas R, Lio P, Lee A, Makris N, Rosen BR, Kwong KK. Activation and habituation in olfaction—an fMRI study. *Neuroimage*. 2001;13:547–560.

23. Rozin P. “Taste-smell confusions” and the duality of the olfactory sense. *Percept Psychophys*. 1982;31:397–401.

24. Spence C. Just how much of what we taste derives from the sense of smell? *Flavour*. BioMed Central; 2015;4:1–10.

25. Naeini AS, Karimi-Galougahi M, Raad N, Ghorbani J, Taraghi A, Haseli S, et al. Paranasal sinuses computed tomography findings in anosmia of COVID-19 [Internet]. *American Journal of Otolaryngology*. 2020. p. 102636. Available from: <http://dx.doi.org/10.1016/j.amjoto.2020.102636>

26. Chetrit A, Lechien JR, Ammar A, Chekkoury-Idrissi Y, Distinguin L, Circiu M, et al. Magnetic resonance imaging of COVID-19 anosmic patients reveals abnormalities of the olfactory bulb: Preliminary prospective study. *J Infect* [Internet]. 2020; Available from: <http://dx.doi.org/10.1016/j.jinf.2020.07.028>

27. Lechien JR, Michel J, Radulesco T, Chiesa-Estomba CM, Vaira LA, De Riu G, et al. Clinical and Radiological Evaluations of COVID-19 Patients With Anosmia: Preliminary Report. *Laryngoscope* [Internet]. 2020; Available from: <http://dx.doi.org/10.1002/lary.28993>

28. Lechien JR, Chiesa-Estomba CM, Hans S, Barillari MR, Jouffe L, Saussez S. Loss of Smell and Taste in 2013 European Patients With Mild to Moderate COVID-19 [Internet]. *Annals of Internal Medicine*. 2020. Available from: <http://dx.doi.org/10.7326/m20-2428>

29. Galougahi MK, Ghorbani J, Bakhshayeshkaram M, Naeini AS, Haseli S. Olfactory Bulb Magnetic Resonance Imaging in SARS-CoV-2-Induced Anosmia: The First Report. *Acad Radiol*. 2020;27:892–3.

30. Eliezer M, Hautefort C, Hamel A-L, Verillaud B, Herman P, Houdart E, et al. Sudden and Complete Olfactory Loss of Function as a Possible Symptom of COVID-19 [Internet]. *JAMA Otolaryngology–Head & Neck Surgery*. 2020. p. 674. Available from: <http://dx.doi.org/10.1001/jamaoto.2020.0832>
31. Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterlé H, et al. Neurologic and neuroimaging findings in COVID-19 patients: A retrospective multicenter study. *Neurology* [Internet]. 2020; Available from: <http://dx.doi.org/10.1212/WNL.0000000000010112>
32. Zambreanu L, Lightbody S, Bhandari M, Hoskote C, Kandil H, Houlihan CF, et al. A case of limbic encephalitis associated with asymptomatic COVID-19 infection. *J Neurol Neurosurg Psychiatry* [Internet]. 2020; Available from: <http://dx.doi.org/10.1136/jnnp-2020-323839>
33. Pilotto A, Masciocchi S, Volonghi I, del Zotto E, Magni E, De Giuli V, et al. The clinical spectrum of encephalitis in COVID-19 disease: the ENCOVID multicentre study [Internet]. Available from: <http://dx.doi.org/10.1101/2020.06.19.20133991>
34. Mori I, Nishiyama Y, Yokochi T, Kimura Y. Olfactory transmission of neurotropic viruses. *J Neurovirol*. 2005;11:129–37.
35. Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients [Internet]. *Journal of Medical Virology*. 2020. p. 552–5. Available from: <http://dx.doi.org/10.1002/jmv.25728>
36. Wilson DA, Rennaker RL. Cortical Activity Evoked by Odors. In: Menini A, editor. *The Neurobiology of Olfaction*. Boca Raton (FL): CRC Press/Taylor & Francis; 2011.
37. Reichert JL, Schöpf V. Olfactory Loss and Regain: Lessons for Neuroplasticity. *Neuroscientist*. 2018;24:22–35.
38. Pellegrino R, Farruggia MC, Small DM, Veldhuizen MG. Beyond olfactory cortex - severity of post-traumatic olfactory loss is associated with response to odors in frontal-parietal-insular networks [Internet]. Available from: <http://dx.doi.org/10.1101/2020.06.09.20118539>
39. Moon W-J, Park M, Hwang M, Kim JK. Functional MRI as an Objective Measure of Olfaction Deficit in Patients with Traumatic Anosmia. *AJNR Am J Neuroradiol*. 2018;39:2320–5.
40. Savic I. Brain imaging studies of the functional organization of human olfaction. *Chem Senses*. 2005;30 Suppl 1:i222-3.
41. Dietemann S, Noblet V, Imperiale A, Blondet C, Namer IJ. FDG PET findings of the brain in sudden blindness caused by bilateral central retinal artery occlusion revealing giant cell arteritis. *Clin Nucl Med*. 2015;40:45–6.
42. Yang TH, Oh SY, Kwak K, Lee JM. Homonymous Visual Field Loss without Structural Lesion on Magnetic Resonance Imaging: Documented with Positron Emission Tomography and Diffusion Tensor Imaging. *Neuroophthalmology* [Internet]. *Neuroophthalmology*; 2014 [cited 2020 Aug 21];38. Available from: <https://pubmed.ncbi.nlm.nih.gov/27928306/>
43. Singh AK, Phillips F, Merabet LB, Sinha P. Why Does the Cortex Reorganize after Sensory Loss? *Trends Cogn Sci*. 2018;22:569–82.
44. Rinck F, Rouby C, Bensafi M. Which format for odor images? *Chem Senses*. Oxford Academic; 2008;34:11–3.

45. Van Toller S. Assessing the Impact of Anosmia: Review of a Questionnaire's Findings. *Chem Senses*. Oxford Academic; 1999;24:705–12.
46. Hu Y, Xu Q, Li K, Zhu H, Qi R, Zhang Z, et al. Gender Differences of Brain Glucose Metabolic Networks Revealed by FDG-PET: Evidence from a Large Cohort of 400 Young Adults [Internet]. *PLoS ONE*. 2013. p. e83821. Available from: <http://dx.doi.org/10.1371/journal.pone.0083821>
47. Kawachi T, Ishii K, Sakamoto S, Matsui M, Mori T, Sasaki M. Gender differences in cerebral glucose metabolism: a PET study [Internet]. *Journal of the Neurological Sciences*. 2002. p. 79–83. Available from: [http://dx.doi.org/10.1016/s0022-510x\(02\)00112-0](http://dx.doi.org/10.1016/s0022-510x(02)00112-0)
48. Yoshizawa H, Gazes Y, Stern Y, Miyata Y, Uchiyama S. Characterizing the normative profile of 18F-FDG PET brain imaging: sex difference, aging effect, and cognitive reserve. *Psychiatry Res*. 2014;221:78–85.